Sonoran Biosciences To Present at Upcoming Conferences
TEMPE, Ariz., Sep. 11, 2026 — Sonoran Biosciences (“Sonoran” or the “Company”), a preclinical-stage pharmaceutical company developing innovative hospital-based products for the treatment of surgical site infections and postoperative pain, announced today it will be presenting at two upcoming conferences.
Sonoran Biosciences will present a research poster “An Injectable Gel Formulation of Bupivacaine (SBG004) Sustains High Local Bupivacaine Levels and is Well-Tolerated” the 2026 Pain Therapeutics Summit, taking place on September 27-28, 2026 at the Hilton San Francisco Airport Bayfront in Burlingame, CA. The content of the poster includes a study comparing bupivacaine concentrations in local tissue sustained by SBG004 in comparison to commercially available extended-release local anesthetics. A copy of the poster may be made available after the conference by contacting the company.
The company will also make an investor presentation at the White Hat Life Science Investor Conference on October 8, 2026 at the Phoenix Convention Center (Phoenix, AZ). The conference is sponsored by the Arizona Bioindustry Association and includes over 30 life science companies from the Rocky Mountain and Southwest regions of the US.
About Sonoran Biosciences
Sonoran Biosciences, Inc. is a privately held specialty pharmaceutical company developing sustained release formulations for the treatment of postoperative pain and surgical site infection (SSI). Sonoran’s lead product is SBG004, an ultra-strong and ultra-long acting extended-release formulation of bupivacaine for acute pain. Sonoran’s products are based on its proprietary SB Gel, an injectable carrier that forms a solid gel in the body, releases drugs over multiple days, and dissolves after the drugs are released.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.